Citations

Mayo Clinic

Showing 10 of 108522 citations.

Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting
Kottschade, Lisa A. , Montane, Heather N. , Tan, Winston, Dronca, Roxana , Seetharam, ­Mahesh , Chen, Ruqin , Block, Matthew S. , Stoff, Ronen, Dronca, Roxana S., Stoff, Ronen , Markovic, Svetomir N. , McWilliams, Robert R. , Dimou, Anastasios , Dudek, Arkadiusz Z. , Tan, Winston

Melanoma Research | August 29, 2024 | Volume: 34 | Issue: 6 | Pages: 510-518

10.1097/cmr.0000000000000997 | PMID 39207855 Get It

Melanoma is the deadliest form of skin cancer. The median age at diagnosis is 66. While most patients are treated with immunotherapy, the use of targeted therapy is a valid alternative for patients whose tumors harbor a BRAF or c-KIT driver mutation. These agents, while effective, come with a variety of side effects which limit their use, especially in older patients. We sought to assess the efficacy and toxicity of these agents in older melanoma patients. Melanoma patients over 65 treated with BRAF/MEK or c-KIT inhibitors were retrospectively identified, and their data were analyzed for treatment efficacy and toxicity. All data were compared using the Chi-square test for categorical comparisons and the Kruskal–Wallis method for median comparisons. One hundred and sixteen patients were identified. One hundred and six patients were treated with BRAF/MEK inhibitors. The assessed response rate (RR) was 83% and was comparable across different subgroups, including advanced line patients and those with a more aggressive disease. The median progression free survival (PFS) was 7.9 months, and the median overall survival (OS) was 15.7 months. Twenty-seven percent experienced grade 3–4 toxicity leading to a 24% treatment discontinuation rate. Another 10 patients were treated with the c-KIT inhibitor imatinib, for whom the assessed RR was 55%. The median PFS was 4.3 months, and the median OS was 22.6 months. Forty percent needed dose reductions, yet none had to stop treatment due to adverse effects. The use of targeted therapy in older patients is effective yet challenging due to toxicity. Deploying mitigation strategies can help maximizing their usefulness.
Simultaneous high‐pitch multi‐energy CT pulmonary angiography using a dual‐source photon‐counting‐detector CT: A phantom experiment
Bruesewitz, Michael R. , Swicklik, Joseph R., Yalon, Mariana , Yu, Lifeng , Mihailovic, Jelena M , Rajiah, Prabhakar S., Mihailović, Jelena M. , Rajiah, Prabhakar , Fletcher, Joel G. , McCollough, Cynthia H. , Yu, Lifeng

Journal of Applied Clinical Medical Physics | August 29, 2024 | Volume: 25 | Issue: 11 | Pages: No page available

10.1002/acm2.14496 | PMID 39207272 Get It

AbstractPurposeA dual‐source CT system can be operated in a high‐pitch helical mode to provide a temporal resolution of 66 ms, which reduces motion artifacts in CT pulmonary angiography (CTPA). It can also be operated in a multi‐energy (ME) mode to provide iodine maps, beneficial in the evaluation of pulmonary embolism (PE). No energy‐integrating detector (EID) CT can perform simultaneous ME and high‐pitch acquisition. This phantom study aimed to evaluate the ability of a photon‐counting‐detector (PCD) CT to perform simultaneous high‐pitch and ME imaging for CTPA.MethodsA motion phantom was used to mimic the respiratory motion. Two tubes filled with iodine with intravascular thrombus mimicked by injecting glue within the tubes were placed along with 5, 10, and 15 mg/mL iodine samples, on a motion phantom at 20 and 30 revolutions per minute. Separate high‐pitch and ME EID‐CT scans and a single high‐pitch ME PCD scan were acquired and virtual monoenergetic images and iodine maps reconstructed. Percent thrombus occlusion was measured and compared between static and moving images.ResultsWhen there was motion, EID‐CT ME suffered from significant motion artifacts. The measured iodine concentrations with PCD‐CT in high‐pitch ME were more stable when there was a motion, with a lower standard deviation than EID‐CT in ME mode. The estimated percent thrombus occlusion dropped significantly with applied motion on EID‐CT, while PCD‐CT high‐pitch ME mode showed good agreement between measurements on static or moving images.ConclusionPCD‐CT with combined ME and high‐pitch mode facilitates simultaneous accurate iodine quantification and assessment of intravascular occlusion.
Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions
Berg, David D. , Patel, Siddharth M. , Alfonso, Carlos E., Alviar, Carlos L. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bennett, Courtney , Gidwani, Umesh , Goldfarb, Michael , Katz, Jason N. , Menon, Venu , Miller, Patrick, Newby, L. Kristin , Papolos, Alexander , Park, Jeong‐Gun , Pierce, Matthew J, Proudfoot, Alastair , Sridharan, Lakshmi , Thompson, Andrea D. , Goldfarb, Michael , Pierce, Matthew , Menon, Venu , Park, Jeong-Gun , van Diepen, Sean , Goldfarb, Michael , Goldfarb, Michael , Berg, David , Thompson, Andrea , Patel, Siddharth M , Pierce, Matthew J , Proudfoot, Alastair G , Bohula, Erin A. , Barnett, Christopher F. , Chaudhry, Sunit‐Preet , Fordyce, Christopher B. , Ghafghazi, Shahab , Miller, P Elliott, Sinha, Shashank S , Diepen, Sean van , Morrow, David A.

European Heart Journal: Acute Cardiovascular Care | August 29, 2024 | Volume: 13 | Issue: 10 | Pages: 709-714

10.1093/ehjacc/zuae098 | PMID 39208447 Get It

Abstract Aims The Shock Academic Research Consortium (SHARC) recently proposed pragmatic consensus definitions to standardize classification of cardiogenic shock (CS) in registries and clinical trials. We aimed to describe contemporary CS epidemiology using the SHARC definitions in a cardiac intensive care unit (CICU) population. Methods and results The Critical Care Cardiology Trials Network (CCCTN) is a multinational research network of advanced CICUs coordinated by the TIMI Study Group (Boston, MA). Cardiogenic shock was defined as a cardiac disorder resulting in SBP < 90 mmHg for ≥30 min [or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain SBP ≥ 90 mmHg] with evidence of hypoperfusion. Primary aetiologic categories included acute myocardial infarction-related CS (AMI-CS), heart failure-related CS (HF-CS), and non-myocardial (secondary) CS. Post-cardiotomy CS was not included. Heart failure-related CS was further subcategorized as de novo vs. acute-on-chronic HF-CS. Patients with both cardiogenic and non-cardiogenic components of shock were classified separately as mixed CS. Of 8974 patients meeting shock criteria (2017–23), 65% had isolated CS and 17% had mixed shock. Among patients with CS (n = 5869), 27% had AMI-CS (65% STEMI), 59% HF-CS (72% acute-on-chronic, 28% de novo), and 14% secondary CS. Patients with AMI-CS and de novo HF-CS were most likely to have had concomitant cardiac arrest (P < 0.001). Patients with AMI-CS and mixed CS were most likely to present in more severe shock stages (SCAI D or E; P < 0.001). Temporary MCS use was highest in AMI-CS (59%). In-hospital mortality was highest in mixed CS (48%), followed by AMI-CS (41%), similar in de novo HF-CS (31%) and secondary CS (31%), and lowest in acute-on-chronic HF-CS (25%; P < 0.001). Conclusion SHARC consensus definitions for CS classification can be pragmatically applied in contemporary registries and reveal discrete subpopulations of CS with distinct phenotypes and outcomes that may be relevant to clinical practice and future research.
Navigating Surgical Emergencies: Small Bowel Obstruction Post- Roux-en-Y Gastric Bypass
Ducás, Alvaro , Laos, Emiliano Manueli, Elli, Enrique F. , Laos, Emiliano G. Manueli , Manueli Laos, Emiliano G , Masrur, Mario A.

No container title available | August 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.172496883.33634152/v1 Get It

Cancer in Patients With Incidental Asymmetric Oropharynx Positron Emission Tomography Uptake
Armstrong, Michael , O’Byrne, Thomas J., Gottlich, Harrison C. , Tasche, Kendall K. , Moore, Eric J. , Gamez, Mauricio E. , Neben-Wittich, M.A. , Price, Katharine A., Lowe, Val J. , Abel, Kathryn M. Van , O'Byrne, Thomas J, Gamez, Mauricio , Lester, Scott C. , Neben-Wittich, Michelle A, Van Abel, Kathryn M , Burkett, Brian J. , Yin, Linda X. , Price, Daniel L. , Routman, David M. , Daniel, J.

JAMA Otolaryngology–Head & Neck Surgery | August 29, 2024 | Volume: 150 | Issue: 12 | Pages: 1078

10.1001/jamaoto.2024.2556 | PMID 39207815 Get It

ImportanceAsymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of malignancy based on this finding is unknown.ObjectiveTo identify the incidence of oropharynx cancer in patients with incidental asymmetric oropharynx PET uptake.Design, Setting, and ParticipantsIn this retrospective cohort study, patients 18 years and older undergoing PET/CT scans at Mayo Clinic between January 2001 and December 2018 were included. Patients with a history or pretest suspicion of oropharynx cancer were excluded. Data were analyzed from March 2021 to December 2023.ExposureBlinded radiologic review of imaging studies, including measurement of maximum standardized uptake values (SUVmax) of the ipsilateral side of concern and contralateral side. Retrospective medical record review for associated clinical data.Main Outcomes and MeasuresThe primary study outcome was the incidence of oropharynx cancer diagnosis in patients with asymmetric oropharynx PET uptake. The primary outcome was formulated before data collection.ResultsOf the 1854 patients identified with asymmetric oropharynx PET uptake, 327 (17.6%) met inclusion criteria. Of these, 173 (52.9%) were male, and the median (range) age was 65.0 (24.8-90.7) years. The mean (SD) follow-up interval was 52.1 (43.4) months. A total of 18 of 327 patients (5.5%) were newly diagnosed with oropharynx cancer. The most common diagnosis was squamous cell carcinoma (n = 9), followed by lymphoma (n = 8), and sarcoma (n = 1). Patients with an incidental diagnosis of oropharynx cancer had higher mean (SD) ipsilateral SUVmax (8.7 [3.7] vs 5.3 [1.9]) and SUVmax ratio (3.0 [1.6] vs 1.6 [0.6]) compared with patients with normal examination findings. SUVmax ratio and difference were found to be good discriminators of oropharynx cancer, with areas under the receiver operating characteristic curve of 86.3% (95% CI, 76.4-94.6) and 85.8% (95% CI, 74.8-94.6), respectively. Patients with a new diagnosis of oropharynx cancer were more likely to have a corresponding CT abnormality than those with normal examination findings (6 of 18 [33%] vs 24 of 295 [8.1%]). Patients with concerning lesions on oropharynx palpation by an otolaryngology health care professional were significantly more likely to be diagnosed with oropharynx cancer compared with patients with normal examination findings (odds ratio, 28.4; 95% CI, 6.6-145.8).Conclusions and RelevanceIn this cohort study, while incidental asymmetric oropharynx PET uptake was common, a new diagnosis of oropharynx cancer was not and potentially results in a large volume of unnecessary referrals and work-up. Using SUVmax ratio, SUVmax difference, and CT correlation may increase the benefit of referral. Patients with a palpable oropharynx lesion and asymmetric oropharynx PET uptake should undergo confirmatory biopsy.
Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system
Muchtar, Eli , Gertz, Morie A. , Mwangi, Raphael , Hassan, Hamza , Leung, Nelson , Dingli, David , Sanchorawala, Vaishali , Dispenzieri, Angela , Leung, Nelson , Sanchorawala, Vaishali , Gertz, Morie A , Muchtar, E , Dingli, David , Hassan, Hamza , Dispenzieri, Angela , Buadi, Francis K. , Staron, Andrew

American Journal of Hematology | August 29, 2024 | Volume: 99 | Issue: 11 | Pages: 2118-2126

10.1002/ajh.27460 | PMID 39207186 Get It

AbstractRenal AL amyloidosis can be complicated by end‐stage renal disease (ESRD) requiring renal replacement therapy (RRT). In this study, we describe the long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation (ASCT) and assess the utility of the renal staging system. Retrospective study of renal AL patients (n = 697; Mayo Clinic, Boston University) who underwent ASCT between 2003 and 2020. Renal stage was assigned based on 24‐h proteinuria and estimated glomerular filtration rate measurements. Renal survival was defined as the time from ASCT until initiation of RRT, while patients who were not placed on RRT were censored at their last follow‐up. With a median follow‐up of 10.4 years, RRT was required in 149 patients (21%). The median time from ASCT to ESRD was 3.4 years, with late events of progression to ESRD seen >10 years from ASCT. Pre‐ASCT renal stage was significantly associated with the cumulative incidence of RRT: 3‐year RRT rate was 3%, 10%, and 37% for renal stages I, II, and III, respectively. However, in the 2012–2020 period subset, a significant decrease in ESRD risk was noted across all renal stages (3‐year RRT 0%, 5%, and 24%, respectively). In multivariate analysis, renal survival was independently associated with the pre‐ASCT renal stage, lambda isotype, bone marrow plasmacytosis ≥20%, post‐ASCT hematologic response, and year of ASCT. Long‐term outcomes of renal AL amyloidosis treated with ASCT are presented. Renal stage reliably predicts renal outcomes in patients with AL undergoing ASCT, despite a reduction in the proportion of patients progressing to RRT in recent years.
Diffusely Infiltrative Small Bowel Disease
Dhillon, Preet , Naidu, Madeline , Olson, Michael C. , VanBuren, Wendaline M. , Sheedy, Shannon P. , Wells, Michael , Fidler, Jeff L. , Heiken, Jay P. , Venkatesh, Sudhakar K. , Kelm, Zachary S. , Wells, Michael L , Venkatesh, Sudhakar K , Fidler, Jeff L.

RadioGraphics | August 29, 2024 | Volume: 44 | Issue: 9 | Pages: No page available

10.1148/rg.230148 | PMID 39207924 Get It

Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS Progression
Andress, Benjamin , Coker, Jonathan, Dasari, Surendra , Murray, David , Willrich, Maria Alice V. , Andress, Benjamin D, Pazdernik, Vanessa M K, Larson, Dirk R. , Coker, Jonathan D, Rajkumar, Vincent, Murray, David L , Willrich, Maria A , Wang, Qian , Pazdernik, Vanessa , Rajkumar, S. Vincent , Dispenzieri, Angela

Clinical Chemistry | August 29, 2024 | Volume: 70 | Issue: 10 | Pages: 1268-1278

10.1093/clinchem/hvae124 | PMID 39206639 Get It

Abstract Background New immunoglobulin free light chain (FLC) assays are available. Despite analytical differences, it seems possible to use free light chain ratios (FLCr) generated by different assays and apply similar cut-points for the diagnosis of multiple myeloma. It is still unknown if we can use different assays for risk stratification of patients with monoclonal gammopathy of undetermined significance (MGUS). Methods Patients diagnosed with MGUS (N = 923) had FLC tested using a nephelometric FreeLite (Binding Site) assay on BNII instruments (Siemens) and a Sebia FLC assay (Sebia) on a DS2 ELISA analyzer (Dynex). Patients were followed up for progression to any plasma cell dyscrasia (PCD) for several decades. The Mayo MGUS risk stratification model for progression was assessed with both assays (M-spike >1.5 g/dL; non-IgG isotype and abnormal FLCr), using package insert reference intervals (RI) and a new metric called principal component 2 (PC2). Results There were 94 events of progression to PCD in the cohort during a median of 38 years of follow-up. Freelite and Sebia FLC showed similar hazard ratios in the risk models for elevated FLCr. An alternative clinical decision point lower than the package insert RI was evaluated for the Sebia assay, which improved risk stratification for patients with a low FLCr. The PC2 metric showed similar performance to the FLCr in models, without superior benefit. Conclusions The Sebia ELISA-based FLC assay can be employed in an MGUS risk stratification model with similar performance to the original 2005 risk stratification model using the FreeLite assay.
Development of a Multiplexed Sphingolipids Method for Diagnosis of Inborn Errors of Ceramide Metabolism
Byeon, Seul Kee , Wegwerth, Peter Jared, George, John Phillip, Oglesbee, Devin , Matern, Dietrich , Pandey, Akhilesh , Kim, Jinyong, Zenka, Roman, George, John P, Vairo, Filippo , Pandey, Akhilesh , Oglesbee, Devin , Byeon, Seul Kee , Kim, Jin Yong , Zenka, Roman M. , Vairo, Filippo Pinto e , Schultz, Matthew

Clinical Chemistry | August 29, 2024 | Volume: 70 | Issue: 11 | Pages: 1366-1374

10.1093/clinchem/hvae115 | PMID 39206579 Get It

Abstract Background Sphingolipids play a crucial role in cellular functions and are essential components of cell membranes, signaling molecules, and lipid metabolism. In particular, ceramide is a key intermediate in sphingolipid metabolism and defects in ceramide metabolism can lead to various inborn errors of metabolism, making ceramides important targets for clinical screening and diagnosis. Detecting altered concentration patterns of sphingolipids is desirable for distinguishing related inborn errors of metabolism for diagnosis and treatment monitoring. Methods We developed a liquid chromatography-tandem mass spectrometry method with a pathway-oriented approach to focus on sphingolipids involved in ceramide metabolism. A total of 47 sphingolipids bearing different head groups and side chains were targeted. Precision/reproducibility, linearity, and spike recovery extraction efficiency tests were performed on plasma and serum samples from confirmed cases of sphingolipidosis. Results Linearity of the method showed the coefficient of determination (r2) for all standards to be >0.99 with a slope of 1.00 ± 0.01. Intra- and interday reproducibility of standards spiked into plasma and serum revealed a coefficient of variation <20%. Spike and recovery assessment showed recovery values of 80%–120% for all standards. Altered levels of sphingolipids from patients with hereditary sensory and autonomic neuropathy caused by pathogenic variants in SPTLC2 and hypomyelinating leukodystrophy related to variants in DEGS1 were detected, in agreement with trends reported in earlier studies confirming the utility of this pathway-centric method. Conclusions This method can serve as a useful tool to simultaneously monitor sphingolipids, enabling screening and diagnosis of inborn errors of ceramide metabolism.
Utilization of an artificial intelligence–enhanced, web‐based application to review bile duct brushing cytologic specimens: A pilot study
Marya, Neil B. , Powers, Patrick, Bois, Melanie C. , Hartley, Christopher , Kerr, Sarah E. , Thangaiah, Judith Jebastin, Cantley, Richard , Gleeson, Ferga C. , Law, Ryan , Martin, John A. , Petersen, Bret T. , Levy, Michael J. , Jebastin, Judith A S , Cantley, Richard , Law, Ryan J, Maleki, Zahra , Pantanowitz, Liron , Petersen, Bret, Marya, Neil B. , Hartley, Christopher P , Norton, Daniel, Dayyeh, Barham K. Abu , Chandrasekhara, Vinay , Gores, Gregory J. , Maleki, Zahra , Petersen, Bret T. , Storm, Andrew C. , Graham, Rondell P.

Cancer Cytopathology | August 29, 2024 | Volume: 132 | Issue: 12 | Pages: 779-787

10.1002/cncy.22898 | PMID 39207803 Get It

Abstract Background The authors previously developed an artificial intelligence (AI) to assist cytologists in the evaluation of digital whole‐slide images (WSIs) generated from bile duct brushing specimens. The aim of this trial was to assess the efficiency and accuracy of cytologists using a novel application with this AI tool. Methods Consecutive bile duct brushing WSIs from indeterminate strictures were obtained. A multidisciplinary panel reviewed all relevant information and provided a central interpretation for each WSI as being “positive,” “negative,” or “indeterminate.” The WSIs were then uploaded to the AI application. The AI scored each WSI as positive or negative for malignancy (i.e., computer‐aided diagnosis [CADx]). For each WSI, the AI prioritized cytologic tiles by the likelihood that malignant material was present in the tile. Via the AI, blinded cytologists reviewed all WSIs and provided interpretations (i.e., computer‐aided detection [CADe]). The diagnostic accuracies of the WSI evaluation via CADx, CADe, and the original clinical cytologic interpretation (official cytologic interpretation [OCI]) were compared. Results Of the 84 WSIs, 15 were positive, 42 were negative, and 27 were indeterminate after central review. The WSIs generated on average 141,950 tiles each. Cytologists using the AI evaluated 10.5 tiles per WSI before making an interpretation. Additionally, cytologists required an average of 84.1 s of total WSI evaluation. WSI interpretation accuracies for CADx (0.754; 95% CI, 0.622–0.859), CADe (0.807; 95% CI, 0.750–0.856), and OCI (0.807; 95% CI, 0.671–0.900) were similar. Conclusions This trial demonstrates that an AI application allows cytologists to perform a triaged review of WSIs while maintaining accuracy.